About Alloy Therapeutics
Alloy Therapeutics is a Healthcare company based in Lexington (United States) founded in 2017 by Zach Serber. Drug discovery services are provided for therapeutic development. Alloy Therapeutics has raised $157 million across 3 funding rounds from investors including ARE, Mubadala and 8VC. The company has 159 employees. Alloy Therapeutics has completed 1 acquisition, including deepCDR Biologics. Alloy Therapeutics was last valued at $1 billion in April 2026. Its website alloytx.com draws about 10 thousand monthly visits. Alloy Therapeutics offers products and services including Antibody Platforms, TCR Mimics, and Genetic Medicines. Its focus areas include Biopharma Outsourcing, CRO and Drug Discovery. Its legal entity is Alloy Therapeutics, Inc. Its competitors include Crown Bioscience, NIH and STAQ Pharma; 2 of its 3 listed competitors have raised funding.
Company details
Alloy Therapeutics was founded in 2017 and is headquartered in Lexington, United States. Operations focus on the biotechnology sector, where drug discovery services are delivered to support pharmaceutical innovation. Expertise is applied in early-stage research and development processes, including target identification and validation. The companys platform facilitates collaborative efforts with partners across the industry, emphasizing efficient workflows in therapeutic advancement.
- Headquarters Lexington, United States
- Employees 159
- Founders Zach Serber
- Stage Unicorn
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website alloytx.com
- Social LinkedIn
- Legal Name Alloy Therapeutics, Inc.
- Total Equity Funding$157M (USD)
in 3 rounds
- Latest Funding Round$40M (USD), Series E
Mar 2026
- InvestorsARE
& 11 more
- Employee Count159
- Investments & Acquisitions
Products & Services of Alloy Therapeutics
Alloy Therapeutics offers a comprehensive portfolio of products and services, including Antibody Platforms, TCR Mimics, and Genetic Medicines.
End-to-end services for monoclonal and bispecific discovery
Platform for targeting intracellular peptides in oncology
Services for improving potency and delivery of ASO candidates
Funding Insights of Alloy Therapeutics
Alloy Therapeutics has successfully raised a total of $157M across 3 strategic funding rounds. The most recent funding activity was a Series E round of $40 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $157M
- Total Rounds 3
- Last Round Series E — $40M
- First Round $75M
(Apr 2021)
- Investors Count 12
All 3 funding rounds of Alloy Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $40M | Series E | – | – | 8VC,JIC Venture Growth Investments |
| Oct 2022 | $42M | Series D | – | 8VC, Mubadala | |
| Apr 2021 | $75M | Series C | – | 8VC, Presight Capital |
| Date | Valuation | Stage |
|---|
Full valuation and stage history of Alloy Therapeutics
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $1B (Apr 2026). 12 investors in total: 11 institutional and 1 angel.
Investors in Alloy Therapeutics
Alloy Therapeutics has secured backing from 12 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include ARE, Mubadala and 8VC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in technology, life sciences, and related sectors. | 8vc.com | |||
Thiel Capital is involved in investment and financial activities. | thielcapital.com | |||
Venture capital fund backed by the Christian family office | presight.vc | West Hollywood, United States | ||
Venture capital investments in technology and defense sectors. | foundersfund.com | |||
| ulyssesholdings.com | ||||
Venture capital investing with a focus on diversity and inclusion in the ecosystem. | gaingels.com | |||
Venture capital fund focused on growth stage companies | j-vgi.co.jp | Minato City, Japan | ||
Investments in tech companies are managed by Calm Ventures. | calmvc.com | Los Angeles, United States | ||
Mubadala Capital is engaged in investment management services. | mubadalacapital.ae | |||
Sovereign wealth fund of United Arab Emirates | 2002 | mubadala.com | Abu Dhabi, United Arab Emirates |
Investor details for Alloy Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alloy Therapeutics
63 people are tracked at Alloy Therapeutics (33 in leadership, 9 in board & advisors, 21 in team); the tracked headcount is 159.
| Name | Role | Group |
|---|---|---|
Zach Serber | Founder | Leadership |
Michael Schmidt | Chief Scientific Officer | Leadership |
Heather Cooke | Senior Director, Bispecific Antibody Engineering | Leadership |
Patrick Jamieson | Chief Operating Officer, Antibody Division | Leadership |
Thomas Vincent | Vp, Antibody Powered Division | Leadership |
Ron Adner | Chief Strategy Advisor | Leadership |
Davide Schiavone | Director & Head, GEO Core | Leadership |
Zhiqian Lucy Liu | VP Head Of Protein Science & Bioanalytics | Leadership |
Nikolai Suslov | Vice President, Antibody Division, Waltham Site Lead | Leadership |
Heather Schwoebel | Chief Business Officer & COO | Leadership |
Dongxing Zha | CTO, TCR Discovery & Engineering & CEO, Keyway TCR Discovery | Leadership |
Rick Shimkets | SVP, Genetics & New Technologies & Head of Antibody Discovery Services, Athens | Leadership |
Errik Anderson | Founder, CEO & Chairman | Leadership |
Vinod Vathipadiekal | Head of Genetic Medicines | Leadership |
Victor Stone | Head of Cell Therapies | Leadership |
Eugene Mironets | Associate Director Of Business Development | Leadership |
Samuel Stimple | Associate Director, Antibody Discovery Programs | Leadership |
Joshua Brandt | Head Of Legal | Leadership |
Paul Benedict | Head Of Information Systems And Scrum Master | Leadership |
Meghan Kelly | Senior Director | Leadership |
43 more people are available in the full profile.
Complete people profiles for Alloy Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alloy Therapeutics
Alloy Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include deepCDR Biologics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Diagnostic and pharmaceutical products are manufactured by deepCDR Biologics. | deepcdr.com | Basel, Switzerland | 2019 | Dec 2021 | •••• |
Complete acquisition details for Alloy Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Alloy Therapeutics
5 dated milestones of Alloy Therapeutics across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Alloy Therapeutics is founded.
- Funding First funding round of $75.0M.
- Acquisition Acquires deepCDR Biologics.
- Funding Latest funding round, Series E, of $40.0M.
- Milestone Reaches Unicorn status.
Competitors of Alloy Therapeutics
Alloy Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Crown Bioscience, NIH and STAQ Pharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| crownbio.com | 2006 | Santa Clara, United States | $85.87M | 18 | Cancer and CVMD drugs are developed using PDX models. | |
| nih.gov | 1887 | United States | Drug discovery services are provided to the biopharma sector. | |||
| staqpharma.com | 2018 | Denver, United States | $33.52M | 30 | Drug discovery services are provided for pharmaceutical innovation. |
Detailed competitors of Alloy Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Alloy Therapeutics
The website of Alloy Therapeutics (alloytx.com) receives about 10.4K visits a month and ranks #1,364,425 among all websites worldwide, #1,771 in Biotechnology and Pharmaceuticals.
- Monthly visits10.4K
▼ 55.7% vs previous month
- Unique visitors11.3K
per month
- Global rank#1,364,425
among all websites
- Category rank#1,771
Health · Biotechnology and Pharmaceuticals
- Bounce rate65%
- Pages per visit1.2
- Average visit5 sec
- DevicesDesktop 12% · Mobile 88%
Websites whose visitors overlap most with Alloy Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| curiaglobal.com | 100% | 29.7K | #736,785 | View details | |
| mixonline.jp | 84% | #252,634 | View details | ||
| fredhutch.org | 50% | 484.8K | #100,633 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Alloy Therapeutics (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alloy Therapeutics
Complete news archive for Alloy Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alloy Therapeutics
Alloy Therapeutics was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Alloy Therapeutics is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Alloy Therapeutics is a funded company, having raised a total of $157M across 3 funding rounds to date. The company's 1st funding round was a Series C of $75M, raised on Apr 2021.
Alloy Therapeutics has 159 employees.
Alloy Therapeutics was founded in 2017 and is headquartered in Lexington, United States. Operations focus on the biotechnology sector, where drug discovery services are delivered to support pharmaceutical innovation. Expertise is applied in early-stage research and development processes, including target identification and validation. The companys platform facilitates collaborative efforts with partners across the industry, emphasizing efficient workflows in therapeutic advancement.
Alloy Therapeutics's top competitors include Crown Bioscience, NIH and STAQ Pharma.
Alloy Therapeutics offers Antibody Platforms, TCR Mimics, and Genetic Medicines.
Alloy Therapeutics has made 1 acquisition, including deepCDR Biologics.
Alloy Therapeutics has 12 investors. Key investors include ARE, Mubadala, 8VC, Thiel Capital, and Presight Capital.
The valuation of Alloy Therapeutics is $1B as of Apr 2026.
Alloy Therapeutics operates through Alloy Therapeutics, Inc..